Format

Send to

Choose Destination
BMC Cancer. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5.

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Author information

1
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy. lpnlra@unife.it.
2
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy. cristian.bassi@gmail.com.
3
Central European Institute of Technology (CEITEC), Molecular Oncology II, University Campus Bohunice Building A3, Kamenice 5, 625 00, Brno, Czech Republic. mlcochovajitka@gmail.com.
4
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy. unclege84@gmail.com.
5
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy. marta.russo@student.unife.it.
6
Central European Institute of Technology (CEITEC), Molecular Oncology II, University Campus Bohunice Building A3, Kamenice 5, 625 00, Brno, Czech Republic. vychytilova.petra@seznam.cz.
7
Central European Institute of Technology (CEITEC), Molecular Oncology II, University Campus Bohunice Building A3, Kamenice 5, 625 00, Brno, Czech Republic. msvoboda@mou.cz.
8
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. msvoboda@mou.cz.
9
Department of Life Sciences and Biotechnology, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy. sbs@unife.it.
10
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. nemecek@mou.cz.
11
Central European Institute of Technology (CEITEC), Molecular Oncology II, University Campus Bohunice Building A3, Kamenice 5, 625 00, Brno, Czech Republic. on.slaby@gmail.com.
12
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. on.slaby@gmail.com.
13
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy. ngm@unife.it.

Abstract

BACKGROUND:

The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in the RAS genes, mutations in other genes, such as BRAF, PI3KCA, or PTEN, could be involved in the resistance to anti-EGFR moAb therapy.

METHODS:

In order to develop a comprehensive approach for the detection of mutations and to eventually identify other genes responsible for resistance to anti-EGFR moAbs, we investigated a panel of 21 genes by parallel sequencing on the Ion Torrent Personal Genome Machine platform. We sequenced 65 CRCs that were treated with cetuximab or panitumumab. Among these, 37 samples were responsive and 28 were resistant.

RESULTS:

We confirmed that mutations in EGFR-pathway genes (KRAS, NRAS, BRAF, PI3KCA) were relevant for conferring resistance to therapy and could predict response (p = 0.001). After exclusion of KRAS, NRAS, BRAF and PI3KCA combined mutations could still significantly associate to resistant phenotype (p = 0.045, by Fisher exact test). In addition, mutations in FBXW7 and SMAD4 were prevalent in cases that were non-responsive to anti-EGFR moAb. After we combined the mutations of all genes (excluding KRAS), the ability to predict response to therapy improved significantly (p = 0.002, by Fisher exact test).

CONCLUSIONS:

The combination of mutations at KRAS and at the five gene panel demonstrates the usefulness and feasibility of multigene sequencing to assess response to anti-EGFR moAbs. The application of parallel sequencing technology in clinical practice, in addition to its innate ability to simultaneously examine the genetic status of several cancer genes, proved to be more accurate and sensitive than the presently in use traditional approaches.

PMID:
26508446
PMCID:
PMC4624582
DOI:
10.1186/s12885-015-1752-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center